The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

AZN ASTRAZENECA PLC ORD SHS $0.25




 Page 3 of 5

Previous | 1 | 2 | 3 | 4 | 5 | Next

Time/Date Code Headline Source Impact
07:00 22-Jan-2015 AZN MAA FOR GOUT TREATMENT LESINURAD ACCEPTED BY EMA RNS +0.01% Up
07:43 14-Jan-2015 AZN BRILINTA PEGASUS STUDY MEETS PRIMARY ENDPOINT RNS +2.29% Up
14:00 02-Jan-2015 AZN Total Voting Rights RNS -0.24% Down
17:40 19-Dec-2014 AZN LYNPARZA APPROVED BY THE US FDA RNS +1.17% Up
07:00 18-Dec-2014 AZN LYNPARZAT APPROVED IN THE EUROPEAN UNION RNS +0.71% Up
07:00 09-Dec-2014 AZN MOVENTIG approved in the EU for OIC RNS -2.28% Down
17:03 05-Dec-2014 AZN Jury verdict favours AZ in Nexium litigation RNS -0.76% Down
07:00 02-Dec-2014 AZN New Drug Application for IRESSA accepted by US FDA RNS -0.23% Down
14:00 01-Dec-2014 AZN Total Voting Rights RNS -0.17% Down
14:00 01-Dec-2014 AZN Blocklisting Interim Review RNS -0.17% Down
07:00 26-Nov-2014 AZN POSITIVE RESULTS FROM BRODALUMAB PHASE III STUDY RNS -0.22% Down
16:00 24-Nov-2014 AZN Publication of Final Terms RNS +0.20% Up
07:00 24-Nov-2014 AZN DUAKLIR GENUAIR APPROVED IN THE EU FOR COPD RNS +0.20% Up
17:00 19-Nov-2014 AZN Launch and Pricing of a EUR750m Bond RNS +1.06% Up
07:00 18-Nov-2014 AZN AZ strategy on track to deliver growth and value RNS +1.21% Up
16:00 17-Nov-2014 AZN Publication of Supplementary Prospectus RNS +0.66% Up
07:00 12-Nov-2014 AZN AMGEN & AZ POSITIVE PHASE III BRODALUMAB RESULTS RNS +1.22% Up
14:27 10-Nov-2014 AZN Director/PDMR Shareholding RNS +1.95% Up
07:04 06-Nov-2014 AZN ASTRAZENECA TO DIVEST MYALEPT TO AEGERION RNS +1.72% Up
07:00 06-Nov-2014 AZN 3rd Quarter Results RNS +1.72% Up

 Page 3 of 5

Previous | 1 | 2 | 3 | 4 | 5 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.


Company Information
Updated Monthly
Company address 2 Kingdom Street, London, W2 6BD, United Kingdom
Company website http://www.astrazeneca....
Market cap(in millions)* £ 51,695.72
Listing/Admission to trading 01 Jun 1993
Trading service -
Market -
Listing category Premium Equity Commercial Companies
*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly.

Trading Information
30-Jun-15
FTSE index FTSE All-Share,FTSE Eurotop 300,FTSE 350 High Yield,FTSE 100,FTSE 350 (ex IT),FTSE techMARK All-Share,FTSE All-Share (ex IT),FTSE 350
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register -
Segment -
MiFID Status -
Exchange market size -
SEDOL -
ISIN number -



ASTRAZENECA share - news analysis